Loading company
$1.63-9.4%Nov 13 close
Figures through December 31, 2025, from the 20-F filed March 31, 2026
Past performance
- 1W
- -3.0%
- 1M
- -46.7%
- 3M
- -82.0%
- 6M
- -90.4%
- 1Y
- -91.7%
$1.63-9.4%Nov 13 close
Figures through December 31, 2025, from the 20-F filed March 31, 2026
From the company’s own 6-K filing.
NeuroSense Therapeutics Ltd. has no earnings call transcript available.
“Our focus remains on advancing PrimeC toward the next stage of development and, ultimately, toward patients,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within approximately 3 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K NeuroSense Therapeutics Ltd. filed on September 25, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.